S&P 500
3,372.85-0.58(-0.02%)Nasdaq
11,019.30-23.20(-0.21%)Russell 2000
1,577.88-1.91(-0.12%)
Valeant Pharmaceuticals International, Inc. (VRX)
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- PR Newswire
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.
CNW GroupBausch Health Announces 2020 Annual Meeting Of Shareholder Results
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
- CNW Group
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
LAVAL, Quebec , Feb. 19, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order to extend and reprice its existing term loan facility and revolving credit facility and make certain other amendments to the terms of the facilities in connection therewith (collectively, the "Credit Agreement Refinancing"). Additionally, the Company intends, subject to market conditions, to have Bausch Health Americas, Inc. ("BHA"), a wholly-owned indirect subsidiary of the Company, issue $3.25 billion of secured debt securities (the "New Debt Securities").
